On June 9, 2007, the U.S. Environmental Protection Agency (EPA) signed three Federal Register notices related to the Nanoscale Materials Stewardship Program (NMSP) under the Toxic Substances Control Act (TSCA) (appended). EPA intends to publish the notices in the July 12, 2007, Federal Register. The first notice announces a public meeting on August 2, 2007, to receive comments on the development of the voluntary NMSP. The second...
On June 22, 2007, the U.S. Environmental Protection Agency (EPA) announced the award of two research grants totaling almost $600,000 to scientists at Oregon State University, who will evaluate whether some engineered nanomaterials adversely affect human health. Under the first research grant, scientists will review a variety of commonly manufactured nanomaterials to determine their potential interactions with biological processes; if the researchers find nanomaterials that produce...
Until September 6, 2007, the European Commission (EC) Scientific Committee on Consumer Products (SCCP) is accepting comments on its Preliminary Opinion on the Safety of Nanomaterials in Cosmetic Products. According to the SCCP, traditional risk assessment methods — hazard identification, hazard characterization, and exposure assessment — may not be suitable for nanomaterials in cosmetics. The SCCP suggests that either a new method should be developed, or...
In the July 2, 2007, Federal Register, the U.S. Environmental Protection Agency (EPA) published a notice regarding its conference entitled “Pollution Prevention through Nanotechnology,” which will be held on September 25-26, 2007, in Arlington, Virginia. EPA intends the conference to provide a forum to exchange ideas and information on using nanotechnology to develop new ways to prevent pollution. Lynn L. Bergeson is on the Steering Committee for the...
The American Bar Association’s (ABA) Section of Environment, Energy, and Resources (SEER) held its latest Nanotechnology Teleconference on June 21, 2007. Entitled “Nanotechnology and Environmental Governance,” the teleconference explored the need for voluntary environmental governance mechanisms to augment the U.S. Environmental Protection Agency’s traditional regulatory programs to manage the issues associated with nanotechnology. The teleconference featured three...
On June 21, 2007, Environmental Defense (ED) and DuPont, who commenced a partnership on nanotechnology in September 2005, released the final Nano Risk Framework, which establishes “a systematic and disciplined process for identifying, managing, and reducing potential environmental, health, and safety risks of engineered nanomaterials across all stages of a product’s ‘lifecycle.’” The Framework is aimed primarily at organizations, both private and public, that are actively...
At its June 22, 2007, meeting, the National Toxicology Program’s (NTP) Board of Scientific Counselors (BSC) reviewed nominations of several substances for testing, including nanoscale silver. The Food and Drug Administration nominated nanoscale silver for toxicological studies “based on (a) increasing widespread use in drug, food and cosmetic products, and (b) the general lack of data on the toxicology and pharmacokinetics of these materials.” Comments on the...
June 26, 2007
Nano-Bio Interaction Workshop Materials Available
The International Council on Nanotechnology (ICON) held a workshop entitled “Towards Predicting Nano-Bio Interactions” on June 5-7, 2007. The plenary presentations and meeting information are now online....
EHP-in-Press published an article entitled “Persistent Tissue Kinetics and Redistribution of Nanoparticles, Quantum Dot 705, in Mice: ICP-MS Quantitative Assessment.” The purpose of the study was to assess the tissue disposition and pharmacokinetics of quantum dots (QD705) in mice. According to the article, the plasma half-life of QD705 in mice was short (18.5 hours), but analyses revealed QD705 persisted and even continued to increase in the spleen, liver, and kidney 28...
On June 4, 2007, the Food and Drug Administration (FDA) announced a new advisory committee intended to counsel FDA on how to strengthen the communication of risks and benefits of FDA-regulated products to the public. The Risk Communication Advisory Committee will:...